People · Operator
Named in public records as an officer, director or promoter · active 2011–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| MultiValent Biotherapies, Inc. | — | Biotechnology | Series A | $10.0M | $25.2M | 2026 |
| Neothera Biosciences, Inc. | — | Biotechnology | Pre-Seed | $671K | $37.1M | 2011 |
Bruce Keyt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bruce Keyt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Fred Schwarzer | 1 | 4 |
| Stephen Snowdy | 1 | 4 |
| Feng Wang-Johanning | 1 | 2 |
| Gary Johanning | 1 | 2 |
| Dongxiao Zhang | 1 | 1 |
| Shirley Clayton | 1 | 1 |
| Deborah Robbins Schwarzer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.